Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From IXICO Plc
Six Chinese biotechs raise a combined $141m in major financing deals backed by venture capital and private equity firms.
The US firm’s oral plasma kallikrein inhibitor was associated with liver elevations in a number of Phase II patients, prompting a trial termination and shift in focus to an on-demand program.
Many gene therapies companies have faced R&D and financial problems this year but the longer term potential of the field and low prices might tempt big pharma into deals.
Having led $30bn of acquisitions of companies at Sanofi, the new challenge for its former global head of partnering is to help make Owkin, “the most disruptive AI biotech company in the world,” he tells Scrip.
- Contract Research, Toxicology Testing-CRO
- Research, Analytical Equipment & Supplies
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- MRI, NMR
- Diagnostic Imaging Equipment & Supplies
- Other Names / Subsidiaries
- IXICO Technologies Inc.
- Optimal Medicine Inc.
- Phytopharm plc